Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang-Nunes, Sandy
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Active, not recruiting	4	313	Europe, US	Teprotumumab, TEPEZZA, Placebo, Saline Solution	Amgen	Thyroid Eye Disease	04/26	04/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
NCT06174064: BroadBand Light for the Treatment of Dry Eye Disease	Not yet recruiting	N/A	60	NA	Broadband Light treatment, Intense Pulsed Light, Sham broadband light treatment	University of Southern California, Ophthalmic Surgeons & Consultants of Ohio, Inc.	Dry Eye Syndromes, Meibomian Gland Dysfunction	07/25	08/25
Jones, Cleo
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Active, not recruiting	4	313	Europe, US	Teprotumumab, TEPEZZA, Placebo, Saline Solution	Amgen	Thyroid Eye Disease	04/26	04/26